Melinta Therapeutics, Inc. clinical trials

Acquired by CorMedix Therapeutics, Aug 29, 2025 · source ↗

The registry lists 34 studies whose lead sponsor is Melinta Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 11, 2026.

Studies

Recruiting first, then most recently updated. Showing 34 of 34. All CorMedix Therapeutics studies →

• A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy AdultsTerminatedNCT06612255Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial InfectionsCompletedNCT02134301Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, LLC · First submitted before Melinta Therapeutics, LLC became part of CorMedix Therapeutics

• Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin InfectionsCompletedNCT05599295Phase 2

  Sponsor listed in the registry: Melinta Therapeutics, LLC · First submitted before Melinta Therapeutics, LLC became part of CorMedix Therapeutics

• A Study to Assess the Cardiac Safety of Oritavancin in Healthy ParticipantsCompletedNCT01762839Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Oritavancin on the Results of Multiple Coagulation Tests in Healthy VolunteersCompletedNCT02357524Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy VolunteersCompletedNCT01784536Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy SubjectsCompletedNCT02470702Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy SubjectsCompletedNCT02340988Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)CompletedNCT01252719Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionCompletedNCT01252732Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Relative Exposure and Safety Study of Kimyrsa in ABSSSI PatientsCompletedNCT03873987Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial PneumoniaCompletedNCT02679573Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin InfectionsCompletedNCT01283581Phase 2

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial PneumoniaWithdrawnNCT03006679Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial PneumoniaTerminatedNCT02605122Phase 2/3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy AdultsCompletedNCT03534622Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated GonorrheaTerminatedNCT02015637Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and APCompletedNCT02166476Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World SettingCompletedNCT03159403

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01984684Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT01811732Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With GonorrheaCompletedNCT02210325Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Pharmacokinetics and Safety of Solithromycin in Adolescents and ChildrenCompletedNCT02268279Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without CirrhosisCompletedNCT02510599Phase 2

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial PneumoniaCompletedNCT01756339Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial PneumoniaCompletedNCT01168713Phase 2

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital GonorrheaCompletedNCT01591447Phase 2

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial PneumoniaCompletedNCT01968733Phase 3

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Pharmacokinetics and Safety of Solithromycin Capsules in AdolescentsCompletedNCT01966055Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy SubjectsCompletedNCT02505997Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Safety and Efficacy Study of Oxazolidinone to Treat PneumoniaCompletedNCT00640926Phase 2

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic ImpairmentCompletedNCT02245243Phase 1

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin InfectionsCompletedNCT00719810Phase 2

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics

• Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin InfectionsCompletedNCT00646958Phase 2

  Sponsor listed in the registry: Melinta Therapeutics, Inc. · First submitted before Melinta Therapeutics, Inc. became part of CorMedix Therapeutics